tag

Sidra Medicine will host the 10th edition of its Qatar Paediatric Emergency Medicine (QPEM 2026), international conference from Friday focusing on the realities of paediatric emergency care. “From its early years, QPEM has evolved from a teaching forum into a platform that actively supports research, quality improvement, and knowledge translation. The conference encourages participants to present original work, audits, and system-level innovations grounded in real clinical environments,” Dr Syed Huda, attending physician and education lead at Emergency Department, Sidra Medicine and the scientific committee chairman of the conference told Gulf Times. Dr Huda noted that discussions at the virtual conference taking place from January 16-18 will centre on high-risk, low-frequency emergencies such as complex paediatric airway management, trauma, sepsis and sudden cardiac or metabolic collapse. “Beyond clinical knowledge, there is strong emphasis on team leadership, human factors, patient safety and decision-making under pressure, recognising that outcomes in paediatric emergencies are shaped as much by systems and teamwork as by individual expertise. QPEM 2026 also addresses the challenges faced by rapidly growing health systems, including overcrowding, resource variability and the need for reliable resuscitation performance across multidisciplinary teams,” explained Dr Huda. According to Dr Huda, by bringing together clinicians, educators, and researchers, QPEM facilitates collaboration across institutions and disciplines, allowing ideas tested locally to be refined, evaluated, and shared regionally. “Importantly, QPEM places value on applied research work that informs practice, improves patient flow, strengthens resuscitation systems, and enhances team performance, ensuring that knowledge generated at the conference has practical impact beyond the lecture hall,” he said. The physician stated that the most significant impact of QPEM has been the development of a shared paediatric emergency care culture across the region. “Over time, the conference has helped standardise approaches to paediatric resuscitation, strengthen interprofessional collaboration, and elevate expectations around safety, leadership, and preparedness. It has contributed to workforce development by supporting trainees, fellows, nurses, and allied health professionals, while also creating a professional network that continues well beyond the conference itself.” He remarked that Sidra Medicine advances paediatric care by combining tertiary clinical services with education, research, and system leadership. “As a dedicated women’s and children’s hospital, it provides highly specialised care for complex paediatric conditions while also serving as a national referral centre. Beyond direct patient care, Sidra Medicine plays a critical role in training the paediatric and emergency workforce, developing clinical pathways, and contributing to international research collaborations. “Its model is intentionally outward-looking, sharing expertise, supporting regional capability building, and aligning care delivery with global best practices adapted to local needs,” added Dr Huda. 

Sidra Medicine has marked a significant medical achievement by securing regulated access to sepiapterin for patients with Phenylketonuria (PKU), positioning Qatar as only the third country worldwide — after Germany and the United States — to provide this breakthrough treatment through approved clinical and governance pathways. The milestone follows the successful administration of sepiapterin to a 12-year-old Qatari girl diagnosed with PKU, a rare inherited metabolic disorder that prevents the body from properly processing phenylalanine, an amino acid found in most protein-containing foods. Phenylketonuria affects approximately 1 in 23,930 newborns worldwide, with higher incidence rates documented in parts of Europe and the Middle East. The condition occurs when the body lacks sufficient amounts of an enzyme called phenylalanine hydroxylase, which is responsible for converting phenylalanine into other substances the body needs. Without this enzymatic activity, phenylalanine accumulates to toxic levels in the blood and brain. Left unmanaged, these elevated levels can cause severe neurological complications including developmental delays, intellectual disability, seizures, behavioral challenges, psychiatric disorders, and learning difficulties. The condition also may cause a musty odor in breath, skin, or urine due to the buildup of phenylalanine byproducts. Traditionally, PKU management has required lifelong adherence to a highly restrictive low-phenylalanine diet, which eliminates most high-protein foods such as meat, dairy, eggs, nuts, and regular bread. Patients must also take specialised medical formulas and nutritional supplements to meet their protein and nutrient needs — a demanding regimen that significantly impacts quality of life, particularly for children and adolescents. Sepiapterin represents a major advancement in PKU care. The medication works by helping the body produce tetrahydrobiopterin (BH4), a natural substance that acts as a cofactor for the phenylalanine hydroxylase enzyme, potentially improving the enzyme's ability to break down phenylalanine. Prof Tawfeg Ben-Omran, Division Chief of Genetics and Genomic Medicine at Sidra Medicine, emphasised the treatment's significance: "Providing access to sepiapterin for patients with PKU represents a transformative step in metabolic care. This treatment can significantly reduce the lifelong burden of strict dietary therapy and improve quality of life for children and adults living with this condition." The achievement represents another important milestone for Sidra Medicine's Gene Therapy Center, launched in January 2025 under the Genetic and Genomic Medicine Clinic. The Center was established to expand access to innovative, life-saving therapies for children with rare and complex genetic disorders throughout the region. Dr Ahmed al-Hammadi, Chair of Pediatric Medicine at Sidra Medicine, added: "This milestone reflects Sidra Medicine's leadership in pediatric rare disease care and Qatar's role as a regional hub for advanced medical therapies. Providing this treatment through strict clinical governance pathways underscores our commitment to ensuring children and their families receive world-class care within Qatar." The Gene Therapy Center employs a multidisciplinary approach, bringing together geneticists, neurologists, therapists, pharmacists, and specialised clinicians to deliver comprehensive, patient-centered care for rare genetic disorders. This collaborative model ensures that treatments like sepiapterin are administered safely and effectively, with appropriate monitoring and support for patients and their families. The successful implementation of sepiapterin therapy positions Qatar at the forefront of rare disease treatment in the Middle East and demonstrates the country's growing capabilities in precision medicine and advanced therapeutics. 

Sidra Medicine has announced the successful completion of its first pediatric allogeneic hematopoietic stem cell transplantation (HSCT), marking an important milestone in its mission to deliver advanced, life-saving care for children with complex and high-risk conditions. A first for Qatar, the procedure was performed on a nine-year-old boy diagnosed with relapsed acute lymphoblastic leukemia, who received stem cells donated by his brother.This transplantation represents a key milestone in Sidra Medicine's pediatric HSCT programme, and follows the opening of its dedicated HSCT ward in June 2025. Chair of Pediatric Medicine at Sidra Medicine, Dr Ahmed al-Hammadi, said: "Completing our first pediatric allogeneic stem cell transplant is a significant achievement for Sidra Medicine and for pediatric care in Qatar. It reflects our commitment to providing world-class specialty care, strengthening national capabilities in advanced cellular therapies, and ensuring that children have access to highly specialised, life-saving treatment within the country". The patient's treatment journey at Sidra Medicine began in 2019, when he underwent standard chemotherapy over two years. Following relapses in May 2022 and December 2024, the medical team determined that an allogeneic stem cell transplant offered the best chance for long-term recovery. Children facing this type of relapse have very limited treatment options without HSCT, highlighting the importance of timely access to this specialised therapy. Acting Chief of Pediatric Hematology, Oncology and HSCT and Director of the Advanced Cell Therapy Core at Sidra Medicine, Dr Chiara Cugno, said: "The continued growth of Sidra Medicine's pediatric HSCT programme reflects the advanced expertise of our hematology and oncology teams. Our services are available to both local and international patients, addressing a critical national need, with more than 50 children in Qatar currently on the transplant waiting list". 

Sidra Medicine, a Qatar Foundation ( QF) entity, began its three day Precision Medicine and the Future of Genomics (PMFG) Summit 2025 Tuesday with an opening ceremony in the presence of Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation, highlighting the advancements in genomics and precision medicine.The opening ceremony was also attended by His Excellency Mansoor bin Ebrahim bin Saad al-Mahmoud, Minister of Public Health; senior officials and government leaders; diplomats as well as high-level representatives from international healthcare and academic institutions.Speaking on the occasion, Dr Iyabo Tinubu-Karch, chief executive officer, Sidra Medicine, noted that at Sidra Medicine, it is not about research alone.**media[389213]**Dr Tinubu-Karch explained: “It is about transforming lives through empathy, personalisation and innovation. Over the past few years, we have seen our vision taking shape and impacting thousands of lives in powerful ways.”“Our work is deeply aligned with Qatar's national priorities. Through precision medicine research and biotechnology, we are supporting economic diversification, the development of human capital, and a resilient health ecosystem, advancing the goals of Qatar National Vision 2030 and the ambitions of Qatar Foundation,” continued the CEO.The official noted that Sidra Medicine is part of a framework that is building a healthier future, not only for one patient, but for the nation and for future generations. “The real outcome is personalised, empathetic care. Together, let us shape a future where innovation, compassion, and national purpose converge, where healthcare is not only advanced, but deeply human,” she added.**media[389214]**Marking the start of the three-day summit, the opening ceremony featured keynote speeches by Julia Vitarello, founder and CEO of Mila's Miracle Foundation, and Prof Ed Liu from The Jackson Laboratory. It concluded with a summit flagship opening panel “From Personalised to Population-Scale: Building a Thriving Precision Medicine Sector in Qatar”.In his opening remarks, Prof Khalid Fakhro, chief research officer, Sidra Medicine said that Sidra Medicine stands as an integrated academic medical centre that combines research, education and clinical care bridging the gap between laboratory discoveries and clinical applications.**media[389215]**“It contributes to strengthening Qatar’s leading role in precision medicine and advanced therapies globally. Today, we take pride in seeing our scientists from various national institutions leading the way regionally and internationally, paving the path toward the medicine of the future—medicine built on personalised treatments that align with each individual’s genetic makeup and disease mechanisms,” stated Prof Fakhro.“Qatar has long recognised—through a far-sighted vision—that true progress can only be achieved through a solid base of science and knowledge. The fruits of this vision are evident in many places, most notably Education City, where schools, universities and research institutes have turned strategic vision into tangible reality, becoming beacons of science and innovation across diverse fields, while also serving as engines of the knowledge economy and pillars of sustainability,” he highlighted.The PMFG Summit 2025, focuses on three major transformative pillars: AI in Genomics, Clinical Trials and Real-World Implementation; and Precision Medicine Implementation/Population Genomics & Future Frontiers, mirroring a comprehensive direction to integrate research, technology, and clinical care into population-scale practice. 

Sidra Medicine, a member of Qatar Foundation, has announced the graduation of 24 high school students from its first Future Doctor Programme, an immersive educational initiative to introduce young learners to the world of modern medicine.The Future Doctor Programme is hosted at Sidra Medicine’s state-of-the-art Simulation Centre and offers students a structured, five-day experience that mirrors real clinical environments. Led by a team of Simulation instructors and cross-departmental clinical educators, the programme includes interactive workshops, multi-station simulation training using advanced manikins, and guided clinical exposure.Prof Ibrahim Janahi, chief medical officer and chair, Medical Education at Sidra Medicine, said: “Nurturing the next generation of healthcare professionals is a core pillar of our mission at Sidra Medicine. The Future Doctor Programme provides students with real, hands-on exposure to the world of medicine and research.We are incredibly proud of the 24 graduates who have demonstrated passion, curiosity, and commitment to learning, playing a role in redefining the future of healthcare in Qatar.” As part of the curriculum, students completed Basic Life Support and CPR accredited by the American Heart Association, alongside introductory skills in first aid, emergency response, and patient communication.The programme is delivered by Sidra Medicine’s clinical and technical experts, ensuring that participants learn in a safe, supportive, and highly specialized environment. Dr Murtada Hammad, director, Medical Education Operations at Sidra Medicine, added: “This programme reflects our belief that early engagement is key to inspiring young people to pursue careers in healthcare. Through simulation, clinical observation, and skill-building activities, students can connect theory with practice in a meaningful way.”

Sidra Medicine, a member of Qatar Foundation (QF), has signed a memorandum of understanding (MoU) with the Qatari Business Women’s Association (QBWA) to promote collaboration in areas that support women’s advancement, leadership, and health.Through this partnership, both organisations will share best practices, exchange expertise, and collaborate to create opportunities that empower women in business, healthcare, and the broader community.The MoU was signed by Dr Iyabo Tinubu-Karch, CEO of Sidra Medicine, and Aisha Hussein Alfardan, vice-chair of QBWA, in the presence of QBWA members and Sidra Medicine’s leadership.Tinubu-Karch said: “We firmly believe that as a healthcare entity that caters to women’s health, our commitment should extend beyond clinical care. This strategic partnership with QBWA reflects our holistic approach to women’s wellbeing and empowerment to become leaders, innovators, and changemakers across all sectors of society.”QBWA is an independent non-profit entity working under the umbrella of the Qatari Businessmen Association (QBA). QBWA’s mission is to provide a platform to empower business and professional women and to unlock the potential of future generations in support of the Qatar National Vision 2030.Alfardan said: “We are proud to partner with Sidra Medicine as a Healthcare Partner, whose dedication to women’s health and wellness aligns with our mission to empower women professionally and socially. Together, we aim to inspire new collaborations that strengthen Qatar’s ecosystem for women’s advancement.”Following the MoU ceremony, the QBWA delegation also attended a tour of several clinics and wards related to women’s services. For more details about Sidra Medicine’s women’s services, visit https://www.sidra.org/services/womens-services

As part of the efforts made by the Qatar government and humanitarian organisations to support the resilience of the people, institutions, and vital sectors of Syria, a high-level delegation from Qatar Red Crescent Society (QRCS) arrived at Damascus International Airport Sunday. The delegation was headed by QRCS president Yousef bin Ali al-Khater, secretary-general Faisal Mohamed al-Emadi, assistant secretary-general for Relief and International Development Mohamed Bader al-Sada, and assistant secretary-general for Communication and Resource Development Mohamed Ahmed al-Beshri. They were received by Syria's Minister of Health Dr Musaab Nazzal al-Ali, Qatar embassy in Syria charge d'affaires Khalifa Abdullah al-Mahmoud, Syrian Arab Red Crescent Society (SARCS) president Dr Mohamed Hazem Bakleh, Damascus Health Directorate director Dr Wael Dagmash, representative of Syria’s ministry of foreign affairs and staff of the QRCS’s representation office in Türkiye. The purpose of the humanitarian visit was to deliver a new batch of aid from Qatar under the “Take Heart Syria” initiative, containing medical equipment and supplies donated by Sidra Medicine, Al-Tafa’ol Trading Company, United International Trading Company, and Doha Health Care Group, in co-ordination with the QRCS, SARCS, and Syria’s ministry of health. The delegation from Qatar arrived at Damascus International Airport aboard a Qatar Amiri Air Force aircraft, carrying 12 tonnes of critical and sophisticated medical equipment to help Syrian hospitals continue providing quality healthcare services for patients. This airlift was preceded by three land aid convoys. On August 28, a total of 22 aid trucks started to depart from the warehouses of Sidra Medicine and the QRCS in Doha in three batches. The convoys travelled through Saudi Arabia and Jordan, ending in Syria, with 78 tonnes of aid. Thus, the total volume of aid delivered under the initiative totaled 90 tonnes of medical equipment and supplies, at a value of over QR45mn. In his keynote speech during the event, al-Khater, said: "These combined efforts were meant to send a message of solidarity to Syria, helping revitalise the Syrian healthcare sector and strengthening the capacity of its medical institutions to meet the needs of millions of Syrians.” “Over the past years, the QRCS implemented large-scale projects and programmes covering various sectors, including health, shelter, emergency relief, food security, water and sanitation, and livelihoods, with a total value of $160mn,” he added. “More than 13mn people across the country benefited from these interventions”. The QRCS president promised to keep working hard to ensure the delivery of more aid from Qatar to the people of Syria, as well as to intensify support to provide the Syrian health sector with the vital supplies needed for medical facilities. “In the name of the Syrian government and people, I would like to welcome this medical shipment from the State of Qatar, through the QRCS,” said Syrian Health Minister Dr al-Ali. “This humanitarian initiative is not merely equipment and supplies, but rather a message of genuine solidarity, a new lease on life for our patients, and a renewed hope for our medical professionals, who continue to do their job despite the difficulties and challenges.” Al-Mahmoud described the aid as a practical demonstration of Qatar’s unwavering commitment to supporting the Syrian people. The SARCS’s Dr Bakleh said that the generous initiative represents the deep fraternal ties between the peoples of Syria and Qatar and best embodies the spirit of humanitarian solidarity. Al-Emadi revealed that the aid shipment from Qatar contained X-ray, anaesthesia, and dialysis equipment; advanced laboratory testing equipment; vital signs monitoring machines; ventilators; incubators; radiography and laser imaging systems; plasma and biological storage freezers; cardiac and neurological monitoring devices; clinical decision support systems; stretchers; disinfection and protection tools; medical consumables; first-aid kits; and other equipment that covers a wide range of healthcare services, as an essential boost to rehabilitate medical infrastructure in Syria and enable hospitals to resume some of their suspended or limited services.

Sidra Medicine, a member of Qatar Foundation, has signed a memorandum of understanding (MoU) with QIIB to explore collaborative pathways that will broaden access to services and create business development opportunities.The MoU was signed between Dr Iyabo Tinubu-Karch, Chief Executive Officer of Sidra Medicine and Dr Abdulbasit Ahmad al-Shaibei, Chief Executive Officer of QIIB. Tinubu-Karch said: “The MoU with QIIB is a testament to Sidra Medicine’s commitment to improving our service delivery model and securing new and innovative ways of providing access to care as well as expanding our brand presence in Qatar.This also highlights our mutual goal to establish partnerships that extends the reach of the banking sector to patient communities.” QIIB is a privately owned Islamic bank in Qatar that offers personal and corporate Islamic banking solutions.The MoU with Sidra Medicine will also seek to establish new access points for patients including healthcare financing options. Dr al-Shaibei stated: “We are pleased at QIIB to sign this memorandum of understanding with Sidra Medicine, which we consider an important milestone in strengthening co-operation with a leading medical institution of distinguished reputation. “We hope that this partnership will contribute to providing innovative solutions that offer patients broader options and support the sustainability of medical services.This collaboration also reflects our commitment to our social role and our drive to build strategic partnerships that align with the Qatar National Vision 2030 and promote comprehensive development.” He added: “At QIIB, we place our commitment to society at the core of our strategy, ensuring that our initiatives are aligned with the Third Financial Sector Strategic Plan launched by the Qatar Central Bank, which places strong emphasis on sustainability and financial inclusion. Through such partnerships, we reaffirm our role in supporting the national economy and contributing to the achievement of sustainable development goals, with positive impact on both individuals and the wider community.”